Mmpip

MMPIP [6-(4-Methoxyphenyl)-5-methyl-3-(4-pyridinyl)-isoxazolo(4,5-c)pyridin-4(5H)-one], ADX71743 [6-(2,4-Dimethylphenyl)-2-ethyl-6,7-dihydro-4(5H)-benzoxazolone], MK-801 [(5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5,10-imine maleate] and DOI (4-Iodo-2,5-dimethoxy-α-methylbenzeneethanamine hydrochloride) were purchased from Tocris Bioscience, Bristol, United Kingdom. For behavioral and pharmacokinetic studies, MK-801 and DOI were dissolved in 0.9% NaCl, MMPIP in 0.5% methylcellulose (Sigma–Aldrich, St Louis, MO, United States) and ADX71743 in small amount of DMSO (Sigma–Aldrich) and then titrated in 20% captisol (Cydex Pharmaceuticals, Lawrence, KS, United States). Final concentration of DMSO in the whole solution was 2%. Control groups received appropriate vehicles. All drugs were administered in a volume of 10 ml/kg when given to mice, and 1 ml/kg when given to rats. The doses of the compounds we used were partially chosen on the basis of the other studies (Hikichi et al., 2010 (link)), but mostly were established experimentally. Mostly, the compounds were administered up to the dose of 15 mg/kg; however, in some case when the activity was evident at the lower doses, the dose of 15 mg/kg was not investigated.